The long-term objective is to develop a new class of small molecule compounds that are neuroprotective and attractive for future drug development. The short term goal is the discovery of compounds that will confer protection from hypoxia-ischemia (HI) induced brain injury, and have the appropriate molecular properties to serve as lead compounds in future drug development. HI induced tissue injury is a major problem across multiple disease areas. HI induced brain injury, such as found in stroke, is of special concern because of the compromised function of individuals who survive as well as the significant number of deaths each year. Currently, there is an unmet need for safe and effective therapies in this major disease area. The clinical presentation of patients is such that the therapeutic window starts four to six hours after trauma, placing a robust demand on candidate new drugs. The spreading of neuronal death away from the site of initial injury in patients and the pathological changes that occur in animal models have focused attention on programmed cell death, but targeting of late stages in the mechanism have proven disappointing. Therefore, targeting early steps in the pathway prior to cell commitment to death is key. Death inducing protein kinases are early in the mechanism, have been identified as potential therapeutic targets, and feasibility studies with kinase inhibitors that cross the blood brain barrier have provided a proof of concept for kinase inhibition preventing HI induced brain injury. We propose to (1) use the co-crystal structures of the target kinase domain containing bound but inactive compounds as the starting point for (2) structure assisted synthetic design, synthesis and testing of focused libraries of potential lead compounds, and (3) validation of final products in an in vivo animal model. We hypothesize that the structure based molecular fragment approach, used in the context of biological considerations of cellular mechanism and clinical needs, will yield the required lead compounds for this high-risk area of research and development. The successful completion will help validate the emerging use of this structure based approach to medicinal chemistry, provide insight into molecular properties key for blood brain barrier penetrance and efficacy in an area of unmet need in CNS discovery chemistry, and generate broadly useful reagents for in vivo signal transduction research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS047586-01
Application #
6718653
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Program Officer
Michel, Mary E
Project Start
2003-09-30
Project End
2007-05-31
Budget Start
2003-09-30
Budget End
2004-05-31
Support Year
1
Fiscal Year
2003
Total Cost
$240,384
Indirect Cost
Name
Northwestern University at Chicago
Department
Pharmacology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Watterson, D Martin; Grum-Tokars, Valerie L; Roy, Saktimayee M et al. (2013) Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One 8:e66226
Chico, Laura K; Watterson, Daniel Martin (2012) The 6th drug discovery for neurodegeneration conference: an intensive course on translating research into drugs. Expert Opin Drug Discov 7:1225-8
Ross, Brian; Tran, Thao; Bhattacharya, Pratip et al. (2011) Application of NMR spectroscopy in medicinal chemistry and drug discovery. Curr Top Med Chem 11:93-114
McNamara, Laurie K; Watterson, D Martin; Brunzelle, Joseph S (2009) Structural insight into nucleotide recognition by human death-associated protein kinase. Acta Crystallogr D Biol Crystallogr 65:241-8
Chico, Laura K; Behanna, Heather A; Hu, Wenhui et al. (2009) Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database. Drug Metab Dispos 37:2204-11
Somera-Molina, Kathleen C; Nair, Sangeetha; Van Eldik, Linda J et al. (2009) Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model. Brain Res 1282:162-72
Karpus, William J; Reynolds, Nathaneal; Behanna, Heather A et al. (2008) Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. J Neuroimmunol 203:73-8
Hu, Wenhui; Ralay Ranaivo, Hantamalala; Roy, Saktimayee M et al. (2007) Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett 17:414-8
Van Eldik, Linda J; Thompson, Wendy L; Ralay Ranaivo, Hantamalala et al. (2007) Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol 82:277-96
Rossi, Janet L; Velentza, Anastasia V; Steinhorn, David M et al. (2007) MLCK210 gene knockout or kinase inhibition preserves lung function following endotoxin-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 292:L1327-34

Showing the most recent 10 out of 18 publications